Clinical and Preventive Efficacy of Interferon Inductor in Viral Respiratory Tract Infections in Children Younger Preschool Age

Харламова, Ф С; Учайкин, В Ф; Кладова, О В; Сергеева, Э. М.; Нестеренко, В. Г.

doi:10.15690/pf.v9i1.169

Cited by 6 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Коэффициент профилактической эффективности составил 64-64,5%. Отмечена хорошая переносимость препарата и отсутствие побочных реакций [12].…”

Section: Bronchopulmonology Otorhinolaryngologyunclassified

“…Проведено проспективное сравнительное исследование на базе детского отделения поликлиники №10 Советского района г. Самары (является клинической базой кафедры детских инфекций Самарского государственного медицинского университета). В исследование вошли 60 детей, средний возраст пациентов был 9,6 (5,(9)(10)(11)(12)(13)(14)7) года, по половому составу несколько преобладали девочки -53,3%.…”

Section: материалы и методыunclassified

See 1 more Smart Citation

Experience of using an interferon inducer in the prevention of influenza and acute respiratory viral infections in children

Borisova,

Bochkareva,

Polezhaeva

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Taking into account the changeable viral landscape of pathogens, the persistence of seasonal morbidity at a high level, and the refusal of a number of parents to be vaccinated against influenza, the interest of scientists and practitioners in the use of endogenous interferon inducers is increasing. Studies by domestic authors have proven that Kagocel® is highly effective in the prevention and treatment of influenza and other ARIs.Aim. Evaluation of the efficacy and safety of Kagocel® for the prevention of influenza and ARIs in children aged 3–18 years old on an outpatient basis during the epidemic rise of respiratory viral infections in 2022–2023.Materials and methods. A prospective comparative analysis of cases of prevention of influenza and ARIs by Kagocel® in children was carried out: group 1 – main (n = 32). Kagocel® was prescribed according to the scheme for a month. The comparison group consisted of patients vaccinated against influenza, who did not receive drugs for the prevention of acute respiratory viral infections: group 2 – comparison (n = 28).Results and discussion. The index of preventive efficacy of Kagocel® was 3.0, the efficiency ratio was quite high – 66.7%. The elimination of the main clinical symptoms of the disease was noted on average by the 2nd–3rd day of illness. Prophylactic administration of the drug allowed to reduce the incidence of influenza and ARIs by 3 times; reduce the number of complications from these diseases by 4 times. The economic feasibility of prophylaxis with Kagocel® has been proven, direct costs for the treatment of one patient have decreased by 3.6 times. The interferon inducer was well tolerated, no side effects of the drug were detected.Conclusion. Endogenous interferon inducer Kagocel® can be used for prophylactic purposes during the seasonal rise in the incidence of influenza and ARIs.

show abstract

Section: Bronchopulmonology Otorhinolaryngologyunclassified

Section: материалы и методыunclassified

Experience of using an interferon inducer in the prevention of influenza and acute respiratory viral infections in children

Borisova,

Bochkareva,

Polezhaeva

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Препарат отечественного производства, индуктор интерферонов Кагоцел, в многочисленных исследованиях показал эффективность при лечении гриппа и ОРВИ у детей с 3-летнего возраста при отсутствии побочных эффектов [8,9,10,11]. Кагоцел (ООО «НИАРМЕДИК ПЛЮС», Россия, регистрационный номер Р N002027/01 от 19.11.07) является высокомолекулярным соединением, синтезированным на основе натриевой соли карбоксиметилцеллюлозы и низкомолекулярного природного полифенола, получаемого из растительного сырья (хлопчатника) путем химического синтеза.…”

Section: Introductionunclassified

Antiviral therapy of acute respiratory viral infection and influenza in children in a hospital

Шарипова¹,

Бабаченко

Левина

et al. 2018

test

View full text Add to dashboard Cite

Objective: to study the efficacy and safety of antiviraltherapy for influenza and acute respiratory viral infection with Kagocel in children in a hospital. Materials and methods: in the observational study included 80 children aged 3 to 11 years, hospitalized with symptoms of influenza and acute respiratory viral infection. The etiological confirmation of the diagnosis was carried out by the PCR method based onthe study of nasal swabs.The drug Kagocel was administered according to the instructions for use during the first 24 hours of hospitalization.The analysis of the virus release after the course of therapy with Kagocel (at 5–6 days from the beginning of treatment) was carried out only in patients with verified influenza and acute respiratory viral infection. Results: the dominant influence of viruses in the development of acute respiratory infections in children aged 3 to 11 years in the period of rising morbidity in St. Petersburg from September 2015 to May 2016. At the same time, 25% of the total number of patients were sick with influenza A and/or B. There was a significant decrease in fever to the third day (p <0,001) and normalization of body temperature from the fourth day after the beginning of therapy with Kagocel in the general group and in patients with confirmed influenza diagnosis. The intoxication syndrome, most pronounced with the flu, was mostly stopped by the fourth day(р<0,001). Catarrhalsyndrome, prevalent in the general group of acute respiratory viral infection, had longer periods of clinical manifestation and against the background of the therapy completely eliminated to the third or seventh day of therapy.Negative PCR results after the course of Kagocel therapy were established in 57,1% of the total group of patients. Among all detected viruses, the most typical is the absence of repeated isolation of influenza B and A viruses, PC virus (86% and 53,8%, 71,4%, respectively), the elimination of rhinoviruses was less frequent (33,3%). Conclusion: according to the results of the study, the effectiveness of therapy with the inclusion of the drug Kagocel in relieving fever by 3–4 days of treatment, as well as intoxication syndrome by 5–6 days in patients with acute respiratory viral infections, including patients with influenza, has been established. Negative results of PCR at the time of completion of therapy occurred mainly in patients with influenza A and B, PC infection. No adverse events were noted.

show abstract

Modern Approaches to the Management of Children with Acute Respiratory Viral Infection

Баранов

Намазова-баранова

Lobzin³

et al. 2023

Pediatr. farmakol.

View full text Add to dashboard Cite

Experts of the Union of Pediatricians of Russia have developed modern guidelines on management of children with acute respiratory viral infection. The term “acute respiratory viral infection” (ARVI) combines following nosological forms: acute nasopharyngitis, acute pharyngitis, acute laryngitis, acute tracheitis, acute laryngopharyngitis, upper respiration tract infection (unspecified). The issues of epidemiology, diagnosis, treatment, and prevention have been considered in detail.

show abstract

Clinical and Preventive Efficacy of Interferon Inductor in Viral Respiratory Tract Infections in Children Younger Preschool Age

Cited by 6 publications

References 2 publications

Experience of using an interferon inducer in the prevention of influenza and acute respiratory viral infections in children

Experience of using an interferon inducer in the prevention of influenza and acute respiratory viral infections in children

Antiviral therapy of acute respiratory viral infection and influenza in children in a hospital

Modern Approaches to the Management of Children with Acute Respiratory Viral Infection

Contact Info

Product

Resources

About